ASH: CSL proves efficacy of hemophilia B gene therapy Hemgenix holds up after 5 years

5th December 2025 Uncategorised 0

After five years of follow-up on its hemophilia B gene therapy Hemgenix, CSL found that a one-time dose cut down on annualized bleeding rates by 90% by the fifth year in its Hope-B study.

More: ASH: CSL proves efficacy of hemophilia B gene therapy Hemgenix holds up after 5 years
Source: fierce